Stock Events

Stock Events

AIxCrypto 

€0
41
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18AugExpected
Q1 2024
Next
Next
-23.94
-23.6
-23.27
-22.94
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 7R90.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap163.06B
Gilead Sciences is a biopharmaceutical company that competes in the development of therapeutics in areas similar to Qualigen, such as viral diseases, making it a direct competitor.
AMGEN
AMGN
Mkt Cap179.12B
Amgen is a biotech firm focusing on human therapeutics, including treatments for illnesses that Qualigen also targets, positioning it as a competitor.
Bristol-Myers Squibb
BMY
Mkt Cap114.68B
Bristol Myers Squibb operates in the biopharmaceutical field, developing prescription drugs that overlap with Qualigen's therapeutic areas.
Pfizer
PFE
Mkt Cap146.36B
Pfizer is a global pharmaceutical corporation with a broad product portfolio that includes treatments in areas competing with Qualigen's focus.
Merck
MRK
Mkt Cap275.09B
Merck & Co. is known for its innovative medicines and vaccines, some of which directly compete with Qualigen's product pipeline.
Abbvie
ABBV
Mkt Cap356.49B
AbbVie is a research-based biopharmaceutical company with a strong emphasis on developing innovative therapies, including those in competition with Qualigen.
Regeneron Pharmaceuticals
REGN
Mkt Cap74.95B
Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of medicines for serious conditions, competing with Qualigen's therapeutic areas.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.09B
Vertex Pharmaceuticals is focused on creating new possibilities in medicine to cure diseases and improve people's lives, including areas where Qualigen operates.
Novartis
NVS
Mkt Cap278.64B
Novartis is a global healthcare company that provides solutions to address the evolving needs of patients worldwide, including in sectors where Qualigen is active.
Astrazeneca
AZN
Mkt Cap283.47B
AstraZeneca is a multinational pharmaceutical and biopharmaceutical company with a wide range of medical therapies that compete with Qualigen's developments.

About

AIxCrypto Holdings, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was formerly known as Qualigen Therapeutics, Inc. and changed its name to AIxCrypto Holdings, Inc. in November 2025. The company was founded in 1996 and is based in Carlsbad, California.
Show more...
CEO
Mr. Kevin A. Richardson II
Employees
4
Country
United States
ISIN
US74754R3012

Listings

MU
DE
7R90.MU
STU
DE
7R90.STU
F
DE
7R90.F
XNAS
US
AIXC

0 Comments

Share your thoughts

FAQ

What is AIxCrypto stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange AIxCrypto stocks are traded under the ticker 7R90.MU.
When is the next AIxCrypto earnings date?▼
AIxCrypto is going to release the next earnings report on August 18, 2026.
How many employees does AIxCrypto have?▼
As of May 12, 2026, the company has 4 employees.
In which sector is AIxCrypto located?▼
AIxCrypto operates in the Health & Wellness sector.
When did AIxCrypto complete a stock split?▼
AIxCrypto has not had any recent stock splits.
Where is AIxCrypto headquartered?▼
AIxCrypto is headquartered in Carlsbad, United States.